The Pursuit of Hepatitis C Elimination: How the Pharmacist Can Make a Difference
Part 2: Understanding the Landscape of Current HCV Treatment
Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
September 10, 2019
September 10, 2020
This activity is intended for clinical pharmacists involved in the care of patients with or at risk for hepatitis C virus (HCV) infection.
This educational activity will provide insight into the critical roles of pharmacists in HCV pretreatment assessment, DAA therapy and monitoring, harm-reduction–informed patient education, and collaborative care models.
After completing this activity, the participant should be better able to:
- Demonstrate knowledge of the efficacy and safety of current direct-acting antiviral (DAA) therapies
- Offer interdisciplinary consultation on DAA management related to comorbidities and drug-drug interactions
- Provide longitudinal pharmacy-based care and harm-reduction–informed counseling for patients before and after HCV treatment
Lucas Hill, PharmD, BCACP, AAHIVP
HIV/HCV Pharmacist Specialist
University of California San Diego Health System
San Diego, California
Susan Lee, PharmD, BCPS, CDE
Sandra Atlas Bass Center for Liver Diseases and Transplantation
Medicine Service Line – Northwell Health
Manhasset, New York
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.o contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008162-9999-19-889-H01-P)
This is a knowledge-based activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
- Lucas Hill, PharmD, BCACP, AAHIVP - Nothing to disclose.
- Susan Lee, PharmD, BCPS, CDE - Nothing to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers, Jeanette Ruby, MD, and Jim Kappler, PhD, have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PIM and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Read or review the activity content.
- Complete the Postactivity Test Questions and Evaluation.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Computer System Requirements
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), or Firefox
MAC OS 10.2.8
Internet Explorer is not supported on the Macintosh.
PIM Contact Information
For information about the accreditation of this program, please contact PIM via e-mail at firstname.lastname@example.org.
Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care
professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing
education for the broad spectrum of health care professionals. This site features a searchable database of accredited
Power-Pak C.E.® courses on important topics for today's health care professionals.
PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants
may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates
for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new
courses available on the site.